학술논문
Seroprevalence of SARS-CoV-2 and Hepatitis B Virus Coinfections among Ethiopians with Acute Leukemia.
Document Type
Article
Author
Source
Subject
*CROSS-sectional method
*RESEARCH funding
*HIV
*ENZYME-linked immunosorbent assay
*DESCRIPTIVE statistics
*REVERSE transcriptase polymerase chain reaction
*LEUKEMIA
*HEPATITIS B
*RESEARCH
*SEROPREVALENCE
*COVID-19
*MIXED infections
*SARS-CoV-2
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
2072-6694
Abstract
Simple Summary: Immunocompromised individuals, including hematological cancer cases, are prone to a high risk of infections such as SARS-CoV-2. Adverse outcomes, including high mortality, were reported in cases infected with SARS-CoV-2 compared with the general population as well as with non-infected malignancy cases. Liver impairment was reported in individuals co-infected with SARS-CoV-2 and other blood borne viruses including HBV. The aim of this study was to assess the SARS-CoV-2 seroprevalence and occurrence of associated infection with HBV among acute leukemia cases in Ethiopia. The findings of this study could potentially increase the clinician awareness of ongoing infections, improve patient care, and support public health strategies. SARS-CoV-2 and blood-borne viral coinfections are well reported. Nevertheless, little is known regarding the seroprevalence of SARS-CoV-2 and coinfection with blood-borne viruses in hematologic malignancy patients in Ethiopia. We aimed to assess the seroprevalence of SARS-CoV-2 and associated infections with hepatitis B and other viruses among adolescent and adult acute leukemia patients at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. A cross-sectional study was conducted from July 2020 to June 2021. Blood samples were tested for the presence of anti-SARS-CoV-2, HBV, HCV, and HIV with ELISA kits and occult hepatitis B infection with a real-time polymerase chain reaction assay. Out of a total 110 cases, the SARS-CoV-2 seroprevalence was 35.5%. The prevalence showed a significant increment from July 2020 to the end of June 2021 (p = 0.015). In 22.7% and 2.7% of leukemia cases, HBV and HIV, respectively, were detected. No HCV was identified. The rate of SARS-CoV-2 coinfection with HBV and HIV was 28% (11/39) and 2.6% (1/39), respectively; however, there was no statistically significant association between SARS-CoV-2 seropositivity with HBV and HIV (p > 0.05). There is a need for viral screening in leukemia cases to monitor infections and inform management. [ABSTRACT FROM AUTHOR]